Such evidence is based on (i) the relevant role played by these nuclear receptors in the control of inflammation in numerous pathological conditions [45, 46]; (ii) the well-described PPARγ-mediated anti-inflammatory activity of certain cannabinoids in different models of central and peripheral inflammation [11]; and (iii) the effects of non-cannabinoid PPARγ activators (e.g., thiazolidinediones [14]) in PD. Here, PPARG is linked to Parkinson disease.